These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 17364459

  • 1. Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate.
    Ravish IR, Nerli RB, Amarkhed SS.
    Arch Androl; 2007; 53(1):17-20. PubMed ID: 17364459
    [Abstract] [Full Text] [Related]

  • 2. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.
    Fenter TC, Davis EA, Shah MB, Lin PJ.
    Am J Manag Care; 2008 May; 14(5 Suppl 2):S154-9. PubMed ID: 18611089
    [Abstract] [Full Text] [Related]

  • 3. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ, Miner M.
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [Abstract] [Full Text] [Related]

  • 4. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
    Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS.
    BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695
    [Abstract] [Full Text] [Related]

  • 5. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H, Lan O, Poulain JE, Comenducci A.
    Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
    [Abstract] [Full Text] [Related]

  • 6. Comparative analysis of alpha-blocker utilization in combination with 5-alpha reductase inhibitors for enlarged prostate in a managed care setting among Medicare-aged men.
    Issa MM, Lin PJ, Eaddy MT, Shah MB, Davis EA.
    Am J Manag Care; 2008 May; 14(5 Suppl 2):S160-6. PubMed ID: 18611090
    [Abstract] [Full Text] [Related]

  • 7. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
    Musquera M, Fleshner NE, Finelli A, Zlotta AR.
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
    [Abstract] [Full Text] [Related]

  • 8. Dutasteride significantly improves quality of life measures in patients with enlarged prostate.
    O'Leary MP, Roehrborn CG, Black L.
    Prostate Cancer Prostatic Dis; 2008 Jul; 11(2):129-33. PubMed ID: 17592479
    [Abstract] [Full Text] [Related]

  • 9. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA, Chung DE, Lee RK, Scofield S, Te AE.
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
    Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C, ARIA3001, ARIA3002 and ARIB3003 Study Investigators.
    Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
    [Abstract] [Full Text] [Related]

  • 11. The effect of dutasteride on the efficacy of photoselective vaporization of the prostate: results of a randomized, placebo-controlled, double-blind study (DOP trial).
    Bepple JL, Barone BB, Eure G.
    Urology; 2009 Nov; 74(5):1101-4. PubMed ID: 19800668
    [Abstract] [Full Text] [Related]

  • 12. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.
    Roehrborn CG, Lukkarinen O, Mark S, Siami P, Ramsdell J, Zinner N.
    BJU Int; 2005 Sep; 96(4):572-7. PubMed ID: 16104912
    [Abstract] [Full Text] [Related]

  • 13. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
    Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS, Dutasteride Alopecia Research Team.
    J Am Acad Dermatol; 2006 Dec; 55(6):1014-23. PubMed ID: 17110217
    [Abstract] [Full Text] [Related]

  • 14. 5alpha-reductase inhibition for men with enlarged prostate.
    Issa MM, Kraft KH.
    J Am Acad Nurse Pract; 2007 Aug; 19(8):398-407. PubMed ID: 17655569
    [Abstract] [Full Text] [Related]

  • 15. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
    Festuccia C, Gravina GL, Muzi P, Pomante R, Angelucci A, Vicentini C, Bologna M.
    J Urol; 2008 Jul; 180(1):367-72. PubMed ID: 18499161
    [Abstract] [Full Text] [Related]

  • 16. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
    Dörsam J, Altwein J.
    Prostate Cancer Prostatic Dis; 2009 Jul; 12(2):130-6. PubMed ID: 19030020
    [Abstract] [Full Text] [Related]

  • 17. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.
    Dolder CR.
    Ann Pharmacother; 2006 Apr; 40(4):658-65. PubMed ID: 16569804
    [Abstract] [Full Text] [Related]

  • 18. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
    Issa MM, Runken MC, Grogg AL, Shah MB.
    Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
    [Abstract] [Full Text] [Related]

  • 19. 5-Alpha reductase inhibitors in men with an enlarged prostate: an evaluation of outcomes and therapeutic alternatives.
    Naslund M, Regan TS, Ong C, Hogue SL.
    Am J Manag Care; 2008 May; 14(5 Suppl 2):S148-53. PubMed ID: 18611088
    [Abstract] [Full Text] [Related]

  • 20. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F, CombAT Study Group.
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.